Fruzaqla

FRUQUINTINIB

Manufacturer: Takeda Pharmaceuticals America, Inc.

Score: 141.0

Quick Summary

Fruzaqla (Fruquintinib) is a kinase inhibitor used for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. The recommended dose is 5 mg orally once daily for the first 21 days of each 28-day cycle. Important safety information includes warnings for hypertension, hemorrhagic events, infections, gastrointestinal perforation, hepatotoxicity, proteinuria, palmar-plantar erythrodysesthesia, and posterior reversible encephalopathy syndrome. Contraindications are none. Special population considerations include use in pregnancy, pediatric use, and geriatric use.

Key Clinical Findings and Indications

Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy
Fruquintinib is a small molecule kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3

Important Safety Information

Warning

Hypertension, hemorrhagic events, infections, gastrointestinal perforation, hepatotoxicity, proteinuria, palmar-plantar erythrodysesthesia, and posterior reversible encephalopathy syndrome

Contraindications

None

Adverse Reactions

Hypertension, palmar-plantar erythrodysesthesia, proteinuria, dysphonia, abdominal pain, diarrhea, asthenia

Dosing Recommendations

General Guidance

Dose reductions for adverse reactions are recommended, with permanent discontinuation for certain adverse reactions

Metastatic colorectal cancer (mCRC)

Adult Dose

5 mg orally once daily for the first 21 days of each 28-day cycle

Pediatric Dose

Not established

Special Population Considerations

Pregnancy

Fruzaqla can cause fetal harm when administered to a pregnant woman
Advise pregnant women of the potential risk to a fetus

Nursing Mothers

Not specified

Pediatric Use

The safety and efficacy of Fruzaqla in patients younger than 18 years of age have not been established

Geriatric Use

No observed overall differences in safety and effectiveness of Fruzaqla in geriatric compared to younger patients

Similar Drugs

Verzenio

ABEMACICLIB

Eli Lilly and Company

Similarity: 64.0%

Gefitinib

GEFITINIB

Natco Pharma USA LLC

Similarity: 62.3%

TUKYSA

TUCATINIB

SEAGEN INC.

Similarity: 62.0%

Gavreto

PRALSETINIB

Genentech, Inc.

Similarity: 62.0%

Gavreto

PRALSETINIB

Rigel Pharmaceuticals, Inc.

Similarity: 62.0%

Fosaprepitant

FOSAPREPITANT

BluePoint Laboratories

Similarity: 61.1%

fosaprepitant

FOSAPREPITANT

Mylan Institutional LLC

Similarity: 61.1%

Fosaprepitant

FOSAPREPITANT

Novadoz Pharmaceuticals LLC

Similarity: 61.1%

Fosaprepitant

FOSAPREPITANT

Fresenius Kabi USA, LLC

Similarity: 61.1%

fosaprepitant

FOSAPREPITANT

Cipla USA Inc.

Similarity: 61.1%

Fosaprepitant

FOSAPREPITANT

Dr. Reddy's Laboratories Inc.,

Similarity: 61.1%

Fosaprepitant

FOSAPREPITANT

MSN LABORATORIES PRIVATE LIMITED

Similarity: 61.1%

Fosaprepitant

FOSAPREPITANT

Dr. Reddy's Laboratories Inc.,

Similarity: 61.1%

FOSAPREPITANT

FOSAPREPITANT

Hepalink USA Inc.

Similarity: 61.1%

Fosaprepitant

FOSAPREPITANT

Dr. Reddy's Laboratories Inc.,

Similarity: 61.1%

Fosaprepitant

FOSAPREPITANT

Fresenius Kabi USA, LLC

Similarity: 61.1%

Fosaprepitant

FOSAPREPITANT

Actavis Pharma, Inc.

Similarity: 61.1%

Fosaprepitant

FOSAPREPITANT

Novadoz Pharmaceuticals LLC

Similarity: 61.1%

Olumiant

BARICITINIB

Eli Lilly and Company

Similarity: 60.8%

Lenvima

LENVATINIB

Eisai Inc.

Similarity: 60.3%

Mekinist

TRAMETINIB

Novartis Pharmaceuticals Corporation

Similarity: 60.0%